Novo Nordisk's US stock rose more than 8% before the market opened. Clinical trials showed that its weight loss drug Amycretin reduced body weight by 22%.
2025-01-24 18:38:33
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up
to date with North American business news.